Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,174 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,174 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the transaction, the chief operating officer now owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $16,108.08.

Twist Bioscience Trading Up 1.1 %

TWST stock opened at $31.08 on Friday. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21. The stock’s fifty day moving average is $34.97 and its two-hundred day moving average is $30.32.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to analysts’ expectations of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The firm’s quarterly revenue was up 31.8% compared to the same quarter last year. During the same period last year, the business posted ($0.74) earnings per share. Equities analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TWST. Scotiabank raised their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TWST. Artisan Partners Limited Partnership increased its holdings in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after purchasing an additional 1,961,621 shares during the period. Invesco Ltd. increased its holdings in shares of Twist Bioscience by 1,496.2% during the third quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock valued at $16,836,000 after purchasing an additional 778,944 shares during the period. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after purchasing an additional 427,274 shares during the period. AEGON ASSET MANAGEMENT UK Plc acquired a new position in Twist Bioscience during the fourth quarter worth about $11,956,000. Finally, Norges Bank acquired a new position in Twist Bioscience during the fourth quarter worth about $10,766,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.